Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Antibiotics

GSK licenses Spero antibiotic for $66 million

by Gina Vitale
October 1, 2022 | A version of this story appeared in Volume 100, Issue 35

 

The structure of tebipenem pivoxil.

GSK will pay $66 million up front to license a late-stage antibiotic from Spero Therapeutics. The drug, tebipenem pivoxil, is the “first oral carbapenem antibiotic to potentially treat complicated urinary tract infections,” the companies say. In June, the US Food and Drug Administration sent Spero a letter outlining deficiencies in its new drug application for tebipenem. The FDA later informed the firm that it could resubmit the application after completing an additional Phase 3 clinical trial. Spero said it would pursue the trial with a partner firm.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.